Harbin Medisan Pharmaceutical Co Ltd - Asset Resilience Ratio
Harbin Medisan Pharmaceutical Co Ltd (002900) has an Asset Resilience Ratio of 2.59% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Harbin Medisan Pharmaceutical Co Ltd to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Harbin Medisan Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See Harbin Medisan Pharmaceutical Co Ltd net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Harbin Medisan Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Harbin Medisan Pharmaceutical Co Ltd (002900) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥93.31 Million | 2.59% |
| Total Liquid Assets | CN¥93.31 Million | 2.59% |
Asset Resilience Insights
- Limited Liquidity: Harbin Medisan Pharmaceutical Co Ltd maintains only 2.59% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Harbin Medisan Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Harbin Medisan Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Huadong Medicine Co Ltd
SHE:000963 |
Drug Manufacturers - Specialty & Generic | 0.05% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
Celltrion Pharm Inc
KQ:068760 |
Drug Manufacturers - Specialty & Generic | 12.49% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
Annual Asset Resilience Ratio for Harbin Medisan Pharmaceutical Co Ltd (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Harbin Medisan Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.27% | CN¥48.08 Million ≈ $7.04 Million |
CN¥3.80 Billion ≈ $556.13 Million |
-0.41pp |
| 2023-12-31 | 1.68% | CN¥57.75 Million ≈ $8.45 Million |
CN¥3.44 Billion ≈ $503.82 Million |
-1.11pp |
| 2022-12-31 | 2.78% | CN¥91.25 Million ≈ $13.35 Million |
CN¥3.28 Billion ≈ $479.50 Million |
-16.19pp |
| 2021-12-31 | 18.97% | CN¥581.68 Million ≈ $85.12 Million |
CN¥3.07 Billion ≈ $448.58 Million |
+4.44pp |
| 2020-12-31 | 14.53% | CN¥360.79 Million ≈ $52.80 Million |
CN¥2.48 Billion ≈ $363.31 Million |
-11.54pp |
| 2019-12-31 | 26.07% | CN¥696.72 Million ≈ $101.95 Million |
CN¥2.67 Billion ≈ $391.02 Million |
+21.90pp |
| 2018-12-31 | 4.17% | CN¥104.91 Million ≈ $15.35 Million |
CN¥2.51 Billion ≈ $367.81 Million |
-- |
About Harbin Medisan Pharmaceutical Co Ltd
Harbin Medisan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale chemical pharmaceutical preparations in China. The company offers various drugs for nervous system, cardiovascular system, systemic anti-infective, muscle and skeletal system, nutritional infusion, and body fluid balance infusion; and other products, including oxaliplatin for injection, calcium foli… Read more